当前位置: 首页 >> 检索结果
61. A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure.
作者: Signe Glargaard.;Jakob Hartvig Thomsen.;Christian Tuxen.;Matias Greve Lindholm.;Christian Axel Bang.;Morten Schou.;Kasper Iversen.;Rasmus Vedby Rasmussen.;Brian Bridal Løgstrup.;Søren Vraa.;Nis Stride.;Ekim Seven.;Anders Barasa.;Marlene Tofterup.;Dan Eik Høfsten.;Kasper Rossing.;Lars Køber.;Finn Gustafsson.;Jens Jakob Thune.
来源: Circulation. 2025年151卷16期1150-1161页
TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion-Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart failure and sizeable pleural effusion.
62. Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.
作者: Brian R Lindman.;Philippe Pibarot.;Allan Schwartz.;J Bradley Oldemeyer.;Yan Ru Su.;Kashish Goel.;David J Cohen.;William F Fearon.;Vasilis Babaliaros.;David Daniels.;Adnan Chhatriwalla.;Hussam S Suradi.;Pinak Shah.;Molly Szerlip.;Michael J Mack.;Thom Dahle.;William W O'Neill.;Charles J Davidson.;Raj Makkar.;Tej Sheth.;Jeremiah Depta.;James T DeVries.;Jeffrey Southard.;Andrei Pop.;Paul Sorajja.;Rebecca T Hahn.;Yanglu Zhao.;Martin B Leon.;Philippe Généreux.; .
来源: Circulation. 2025年151卷22期1550-1564页
The EARLY TAVR trial (Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis) demonstrated that early transcatheter aortic valve replacement (TAVR) intervention was superior to clinical surveillance with delayed TAVR in patients with asymptomatic severe aortic stenosis. Cardiac biomarkers are associated with maladaptive remodeling, symptom onset, and worse outcomes after TAVR. Whether elevated biomarkers identify asymptomatic patients more likely to benefit from early intervention is unknown.
63. Short-Term DAPT After Complex PCI With Third-Generation DES: A Post Hoc Analysis of the HOST-IDEA Trial.
作者: Jung-Kyu Han.;Keehwan Lee.;Sang-Hyeon Park.;Seokhun Yang.;Doyeon Hwang.;Jeehoon Kang.;Han-Mo Yang.;Kyung Woo Park.;Hyun-Jae Kang.;Bon-Kwon Koo.;Seung-Ho Hur.;Weon Kim.;Sang-Hyun Park.;Seung Hwan Han.;Sang-Hyun Kim.;Yong Hoon Kim.;Namho Lee.;Seung Jin Lee.;Sanghoon Shin.;Hyo-Soo Kim.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014623页
The optimal duration of dual antiplatelet therapy (DAPT) after complex percutaneous coronary intervention (PCI) remains unclear. We aim to investigate the efficacy and safety of 3 to 6 months of DAPT over 12 months after complex PCI.
64. Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: A Randomized Clinical Trial.
作者: Varsha Keelara Tanguturi.;Roukoz Abou-Karam.;Fangzhou Cheng.;Rong Duan.;Ignacio Inglessis-Azuaje.;Nathaniel B Langer.;Evin N Yucel.;Jonathan J Passeri.;Judy W Hung.;Sammy Elmariah.
来源: Circulation. 2025年151卷21期1498-1507页
Symptomatic severe aortic stenosis (AS) remains undertreated with high resultant mortality despite increased growth and availability of aortic valve replacement (AVR) since the advent of transcatheter therapies. We evaluate the impact of electronic provider notifications (EPNs) on rates of AVR at 1 year.
65. Effect of Red Blood Cell Transfusion Strategy on Clinical Outcomes Among Patients With Acute Myocardial Infarction Undergoing Revascularization: A Prespecified Analysis of the MINT Trial.
作者: Sunil V Rao.;Maria Mori Brooks.;Helen E A D'Agostino.;P Gabriel Steg.;Tabassome Simon.;Herbert D Aronow.;Andrew M Goldsweig.;Shahbaz Malik.;Caroline Alsweiler.;Kalon K L Ho.;Payam Dehghani.;Adriano Caixeta.;Ata R Quraishi.;Simon Robinson.;Jay H Traverse.;Omar Siddiqi.;Dean A Fergusson.;Brian J Potter.;Joshua Schulman-Marcus.;Friederike K Keating.;Jeffrey L Carson.; .
来源: Circ Cardiovasc Interv. 2025年18卷5期e015249页
The MINT trial (Myocardial Ischemia and Transfusion; N=3504) randomized patients with acute myocardial infarction (MI) and hemoglobin ≤10 g/dL to liberal (maintain hemoglobin ≥10 g/dL) or restrictive (maintain hemoglobin ≥8 g/dL) red blood cell transfusion. The results suggested a benefit on 30-day death or MI with a liberal transfusion strategy. The effect of transfusion in patients with acute MI undergoing revascularization is unclear.
66. Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Controlled Trial.
作者: Saibal Kar.;Raj R Makkar.;Brian K Whisenant.;Nadira Hamid.;Hursh Naik.;Peter Tadros.;Matthew J Price.;Gagan Singh.;Jonathan G Schwartz.;Samir Kapadia.;Oluseun Alli.;Samuel Horr.;Puvi Seshiah.;Wayne Batchelor.;Brandon M Jones.;Mustafa I Ahmed.;Raymond Benza.;Ulrich Jorde.;Vinod H Thourani.;Andrew A Ghobrial.;Gilbert H L Tang.;Phillip M Trusty.;Dina Huang.;Rebecca T Hahn.;David H Adams.;Paul Sorajja.; .
来源: Circulation. 2025年151卷23期1630-1638页
One-year outcomes of TRILUMINATE Pivotal (Trial to Evaluate Cardiovascular Outcomes in Patients Treated With the Tricuspid Valve Repair System Pivotal) found that transcatheter edge-to-edge repair (TEER) for the treatment of severe, symptomatic tricuspid regurgitation improved quality of life compared with medical therapy alone with similar rates of mortality and heart failure hospitalization. However, additional follow-up is necessary to determine the prolonged benefits of tricuspid TEER.
67. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
作者: Nikolaus Marx.;John E Deanfield.;Johannes F E Mann.;Rosario Arechavaleta.;Stephen C Bain.;Harpreet S Bajaj.;Katrine Bayer Tanggaard.;Andreas L Birkenfeld.;John B Buse.;Zaklina Davicevic-Elez.;Cyrus Desouza.;Scott S Emerson.;Mads D M Engelmann.;G Kees Hovingh.;Silvio E Inzucchi.;Pardeep S Jhund.;Sharon L Mulvagh.;Rodica Pop-Busui.;Neil R Poulter.;Søren Rasmussen.;Shih-Te Tu.;Darren K McGuire.; .
来源: Circulation. 2025年151卷23期1639-1650页
Both GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT2 (sodium-glucose cotransporter-2) inhibitors (SGLT2i) improve cardiovascular outcomes in people with type 2 diabetes and cardiovascular or chronic kidney disease. However, there are limited data about the effect of combining these agents on cardiovascular and safety outcomes.
68. Effect of Disclosing a Polygenic Risk Score for Coronary Heart Disease on Adverse Cardiovascular Events.
作者: Mohammadreza Naderian.;Marwan E Hamed.;Ali A Vaseem.;Kristjan Norland.;Ozan Dikilitas.;Azin Teymourzadeh.;Kent R Bailey.;Iftikhar J Kullo.
来源: Circ Genom Precis Med. 2025年18卷2期e004968页
In the Myocardial Infarction Genes clinical trial (URL: https://www.clinicaltrials.gov; Unique identifier: NCT01936675), participants at intermediate risk of coronary heart disease (CHD) were randomized to receive a Framingham risk score (Framingham risk score group, n=103) or an integrated risk score (integrated risk score group [IRSg], n=104) that additionally included a polygenic risk score. After 6 months, IRSg participants had higher statin initiation and lower low-density lipoprotein cholesterol. We conducted a post hoc 10-year follow-up analysis to investigate whether disclosure of a polygenic risk score for CHD was associated with a reduction in major adverse cardiovascular events (MACE).
69. Alcohol Exposure Among Patients With Dilated Cardiomyopathy and Their First-Degree Relatives: The DCM Precision Medicine Study.
作者: Javier Jimenez.;Hanyu Ni.;Stuart D Katz.;Garrie J Haas.;Jinwen Cao.;Muni Rubens.;Sandra Chaparro.;Anshul Saxena.;Mark Hofmeyer.;Evan Kransdorf.;Gregory A Ewald.;Alanna A Morris.;Anjali Owens.;Brian Lowes.;Douglas Stoller.;W H Wilson Tang.;Palak Shah.;Jane E Wilcox.;Frank Smart.;Jessica Wang.;Stephen S Gottlieb.;Daniel P Judge.;Jonathan O Mead.;Natalie Hurst.;Patricia K Parker.;Gordon S Huggins.;Elizabeth Jordan.;Daniel D Kinnamon.;Ray E Hershberger.; .
来源: Circ Genom Precis Med. 2025年18卷2期e004946页
Whether prolonged and excessive alcohol consumption contributes to dilated cardiomyopathy (DCM) remains uncertain. This study aimed to describe the prevalence of alcohol use in patients with DCM and their first-degree relatives (FDRs) and determine if cumulative alcohol exposure associates with DCM/partial DCM or modifies the association of DCM with DCM-relevant rare variants.
70. Blood Transfusion in Patients With Acute Myocardial Infarction, Anemia, and Heart Failure: Lessons From MINT.
作者: Andrew M Goldsweig.;William J Kostis.;Brandon M Herbert.;Claire Bouleti.;Brian J Potter.;Jordan B Strom.;Jocelyne Benatar.;Thao Huynh.;Srikanth Vallurupalli.;Estêvão Lanna Figueiredo.;J Dawn Abbott.;Howard A Cooper.;Andrew P DeFilippis.;Dean A Fergusson.;Shaun G Goodman.;Paul C Hébert.;Renato D Lopes.;Sunil V Rao.;Tabassome Simon.;Jeffrey L Carson.;Maria Mori Brooks.;John H Alexander.; .
来源: Circ Heart Fail. 2025年18卷4期e012495页
Blood transfusion may precipitate adverse outcomes, including heart failure (HF), among patients with acute myocardial infarction (MI). This study characterizes the effects of a restrictive or liberal transfusion strategy on outcomes in patients with MI and anemia with and without baseline HF.
71. Effects of Nicorandil, Isosorbide Mononitrate, or Diltiazem on Radial Artery Grafts After CABG: The Randomized ASRAB-Pilot Trial.
作者: Yunpeng Zhu.;Wei Zhang.;Kaijie Qin.;Yun Liu.;Haoyi Yao.;Zhe Wang.;Xiaofeng Ye.;Mi Zhou.;Haiqing Li.;Jiapei Qiu.;Hong Xu.;Yanjun Sun.;Mario Gaudino.;Qiang Zhao.
来源: Circ Cardiovasc Interv. 2025年18卷4期e014542页
The optimal antispastic treatment after coronary artery bypass grafting using radial artery (RA) grafts is controversial. This clinical trial aimed to generate pilot comparative data on the effects of nicorandil, isosorbide mononitrate, or diltiazem on RA grafts.
72. Enhancing Stroke Awareness and Activation Among High-Risk Populations: A Randomized Direct Mail Intervention in Diverse Healthcare Settings.
作者: Christine C Groves.;Teresa M Damush.;Laura J Myers.;Fitsum Baye.;Joanne K Daggy.;Anthony J Perkins.;Holly Martin.;Layne Mounsey.;Daniel O Clark.;Linda S Williams.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷5期e011425页
Many patients are unaware of their stroke risk. The purpose of this research was to compare the effect of behaviorally tailored mailed messages on patient activation to reduce stroke risk.
73. Operator Radiation Exposure Comparing the Left Radial Artery Approach and a Uniform Hyper-Adducted Right Radial Artery Approach: The HARRA Study.
作者: Richard Casazza.;Bilal Malik.;Arsalan Hashmi.;Joshua Fogel.;Enrico Montagna.;Robert Frankel.;Elliot Borgen.;Sergey Ayzenberg.;Michael Friedman.;Norbert Moskovits.;Shivani Verma.;Jamie Meng.;Nailun Chang.;Yili Huang.;Carlos Rodriguez.;Habib Hymie Chera.;Shiv Raj.;Saurav Chaterjee.;Daren Gibson.;Andres Palacios.;Chirag Agarwal.;Maria Victoria Nene.;Jacob Shani.
来源: Circ Cardiovasc Interv. 2025年18卷4期e014602页
Radiation exposure is one of the most adverse occupational hazards faced by interventional cardiologists. Various arterial access sites have shown to yield different operator radiation exposure during diagnostic cardiac catheterization.
74. Impact of Bypass Conduit and Early Technical Failure on Revascularization for Chronic Limb-Threatening Ischemia.
作者: Michael S Conte.;Alik Farber.;Andrew Barleben.;Emiliano Chisci.;Gheorghe Doros.;Vikram S Kashyap.;Ahmed Kayssi.;Philippe Kolh.;Carla C Moreira.;Timothy Nypaver.;Kenneth Rosenfield.;Vincent L Rowe.;Andres Schanzer.;Niten Singh.;Jeffrey J Siracuse.;Michael B Strong.;Matthew T Menard.
来源: Circ Cardiovasc Interv. 2025年18卷3期e014716页
The optimal strategy for lower extremity revascularization (surgical bypass versus endovascular intervention) in patients with chronic limb-threatening ischemia (CLTI) is unclear. We examined the effectiveness of open surgical bypass using single-segment great saphenous vein conduit (SSGSV), alternative conduits (AC), or endovascular interventions (ENDO) among patients with CLTI deemed acceptable for either open surgical bypass or ENDO treatment.
75. Intravascular Imaging-Guided Versus Angiography-Guided Complex PCI in Patients With High Bleeding Risk: A Secondary Analysis of the RENOVATE-COMPLEX PCI Trial.
作者: Jinhwan Jo.;Sang Yoon Lee.;Woochan Kwon.;Seung-Jae Lee.;Jong-Young Lee.;Seung Hun Lee.;Doosup Shin.;Sang Min Kim.;Kyeong Ho Yun.;Jae Young Cho.;Chan Joon Kim.;Hyo-Suk Ahn.;Chang-Wook Nam.;Hyuck-Jun Yoon.;Yong Hwan Park.;Wang Soo Lee.;Ki Hong Choi.;Taek Kyu Park.;Jeong Hoon Yang.;Seung-Hyuk Choi.;Hyeon-Cheol Gwon.;Young Bin Song.;Joo-Yong Hahn.;Sang Yeub Lee.;Joo Myung Lee.; .
来源: Circ Cardiovasc Interv. 2025年18卷3期e014952页
Although patients with high bleeding risk (HBR) often have complex coronary artery lesions, it is not known whether intravascular imaging-guided percutaneous coronary intervention (PCI) improves their prognosis. We sought to investigate the benefit of intravascular imaging-guided PCI for complex coronary artery lesions in patients with HBR.
76. Macitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension Study.
作者: Sanjiv J Shah.;Diana Bonderman.;Barry A Borlaug.;John G F Cleland.;Gabriela Lack.;Wentao Lu.;Adriaan A Voors.;Faiez Zannad.;Mark T Gladwin.
来源: Circ Heart Fail. 2025年18卷3期e011381页
Despite favorable hemodynamic and neurohormonal effects, endothelin receptor antagonists have not improved outcomes in patients with heart failure (HF), possibly because they cause fluid retention.
77. Patent Foramen Ovale Closure in Patients With and Without Nickel Hypersensitivity: A Randomized Trial.
作者: Anastasios Apostolos.;Stamatios Gregoriou.;Maria Drakopoulou.;Georgios Trantalis.;Aikaterini Tsiogka.;Nikolaos Ktenopoulos.;Konstantina Aggeli.;Alexander Stratigos.;Konstantinos Tsioufis.;Konstantinos Toutouzas.
来源: Circ Cardiovasc Interv. 2025年18卷4期e015228页
Nickel-containing devices, such as the Amplatzer PFO Occluder and Gore Cardioform Septal Occluder, are used for transcatheter patent foramen ovale closure. However, the impact of nickel hypersensitivity on postprocedural outcomes remains poorly understood. This study aimed to evaluate the risk of adverse events in patients with nickel hypersensitivity undergoing patent foramen ovale closure.
78. Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy.
作者: Natasha L Altman.;Edward A Gill.;Rami Kahwash.;Leslie K Meyer.;Jessica A Wagner.;Anis Karimpour-Fard.;Amber A Berning.;Wayne A Minobe.;Ian A Carroll.;Eric R Jonas.;Dobromir Slavov.;Sitaramesh Emani.;William T Abraham.;Alexa R Gollah.;Samuel L Ellis.;Matthew R G Taylor.;Sharon L Graw.;Luisa Mestroni.;Timothy A McKinsey.;Peter M Buttrick.;David P Kao.;Michael R Bristow.
来源: Circ Heart Fail. 2025年18卷4期e012484页
Heart rate (HR) affects heart failure outcomes, via uncertain mechanisms that may include left ventricular remodeling. However, in human ventricular myocardium, HR change has not been associated with a particular remodeling molecular phenotype.
79. Evaluating the Appropriate Use Criteria for Coronary Revascularization in Stable Ischemic Heart Disease Using Randomized Data From the ISCHEMIA Trial.
作者: James Slater.;David J Maron.;Philip G Jones.;Sripal Bangalore.;Harmony R Reynolds.;Zhuxuan Fu.;Gregg W Stone.;Ruth Kirby.;Judith S Hochman.;John A Spertus.; .
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷3期e010849页
The appropriate use criteria for revascularization of stable ischemic heart disease have not been evaluated using randomized data. Using data from the randomized ISCHEMIA trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches; July 2012 to January 2018, 37 countries), the health status benefits of an invasive strategy over a conservative one were examined within appropriate use criteria scenarios.
80. Left Ventricular Entry to Reduce Brain Lesions During Catheter Ablation: A Randomized Trial.
作者: Gregory M Marcus.;Roderick Tung.;Edward P Gerstenfeld.;Trisha F Hue.;Feng Lin.;Jing Cheng.;J Peter Weiss.;Wendy S Tzou.;Henry Hsia.;Ashkan Ehdaie.;Daniel H Cooper.;T Jared Bunch.;Jeffrey Arkles.;Babak Nazer.;Adam Lee.;Alexios Hadjis.;Duy T Nguyen.;Mihail G Chelu.;Joshua Moss.;Jonathan C Hsu.;Miguel Valderrábano.;Prashant D Bhave.;Andrew D Beaser.;Arvindh Kanagasundram.;Oussama Wazni.;Jason Bradfield.;Grace Wall.;Kathleen Chang.;Michelle Yang.;Gabrielle Montenegro.;Sabrina Jarrott.;Joel H Kramer.;Anthony S Kim.;Yvonne M Morris.;William P Dillon.
来源: Circulation. 2025年151卷15期1051-1059页
Catheter ablation of ventricular arrhythmias, one of the most rapidly growing procedures in cardiac electrophysiology, is associated with magnetic resonance imaging-detected brain lesions in more than half of cases. Although a retrograde aortic approach is conventional, modern tools enable entry through a transseptal approach that may avoid embolization of debris from the arterial system. We sought to test the hypothesis that a transseptal puncture would mitigate brain injury compared with a retrograde aortic approach.
|